MedTrace Logo

Colchicine After Electrocardioversion for Atrial Fibrillation

NCT05890664 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 416

Last updated 2025-05-28

No results posted yet for this study

Summary

The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.

Conditions

Interventions

DRUG

Colchicine

Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide. Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether.

DRUG

Placebo

Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.

Sponsors & Collaborators

  • Swiss Heart Foundation

    collaborator OTHER

  • Fondation Machaon, Switzerland, Genf

    collaborator UNKNOWN

  • Foundation for Cardiovascular Research Basel

    collaborator UNKNOWN

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Philipp Krisai, PD Dr. med. · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-14
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05890664 on ClinicalTrials.gov